Compare TUSK & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | BNR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 126.5M |
| IPO Year | 2016 | 2019 |
| Metric | TUSK | BNR |
|---|---|---|
| Price | $2.83 | $16.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 73.9K | 65.9K |
| Earning Date | 10-30-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $44,292,000.00 | N/A |
| Revenue This Year | N/A | $101.46 |
| Revenue Next Year | N/A | $14.81 |
| P/E Ratio | $32.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $6.79 |
| 52 Week High | $3.92 | $41.72 |
| Indicator | TUSK | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | N/A |
| Support Level | $2.80 | N/A |
| Resistance Level | $2.94 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 7.07 | 0.00 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.